"乙肝"标签列表

Effect of Infliximab on the Efficacy of Peginterferon alfa-2b(PEG-2b) Plus Ribavirin(RBV) (2)2007-11-14

Effect of Infliximab on the Efficacy of Peginterferon alfa-2b(PEG-2b) Plus Ribavirin(RBV) (3)2007-11-14

Effect of Infliximab on the Efficacy of Peginterferon alfa-2b(PEG-2b) Plus Ribavirin(RBV) (1)2007-11-14

Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin(4)2007-11-13

Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin(5)2007-11-13

Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin(2)2007-11-13

Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin(3)2007-11-13

Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin(1)2007-11-13

HBV Core Curriculum:Current Treatment Options for Hepatitis B2007-11-08

在用聚乙二醇化干扰素 alfa-2b治疗的 HBeAg-阳性患者中 HBV 基因型可作为HBsAg 转阴预测因子2007-11-08

临床HBV治疗更新2007-11-08

DIRECT试验（每日剂量一致的干扰素和利巴韦林：联合治疗的疗效）：既往聚乙二醇干扰素加利巴韦林治疗无应答的治疗：持续病毒学应答数据2007-11-07

慢性乙型肝炎一线治疗选择2007-11-07

乙型肝炎病毒耐药：临床医生为临床观众的概述 2007-11-07

慢性乙型肝炎治疗路线图解读2007-11-06

干扰素受体基质-1和HBx基因双重过表达引起的肝脏恶化前改变2007-11-06

替诺福韦对核苷类药物应用的HBV单纯感染患者疗效的多中心初步评估2007-11-06

辩论：拉米夫定耐药HBeAg-阴性患者最优管理策略是什么？2007-11-05

辩论：最好的拯救管理初始治疗无应答患者的策略是什么：换药或加药？2007-11-05

慢性乙型肝炎治疗新策略-最新乙型肝炎防治指南解读 任红2007-08-08